Citizens has reasserted a Market Outperform rating for Hinge Health Inc (NYSE:HNGE) and held its price target at $65.00 after conducting industry-level due diligence on the company.
The firm’s $65 target equates to an approximate 73% upside from Hinge Health’s prevailing share price of $37.65. Citizens noted that this view is consistent with a broader analyst consensus that remains constructive, with price targets from other research houses spanning $48 to $72.
Citizens made its pronouncement in the wake of a competitive development in the digital musculoskeletal (MSK) market: Sword Health’s announcement that it is acquiring Kaia Health, a fellow digital MSK provider. Citizens’ update comes ahead of Hinge Health’s fourth-quarter 2025 results, which the company plans to report on February 10 after the market close.
The research firm observed that Hinge Health shares have climbed 18% since the company’s initial public offering on May 22, 2025. By comparison, the Russell 3000 index rose 20% over the same post-IPO interval, according to the figures cited by Citizens.
Analysts from multiple firms have been active on Hinge Health recently, reflecting sustained research coverage and interest in the company’s position within the MSK segment:
- Freedom Capital Markets initiated coverage with a Buy rating and set a $59 price target, noting a reported growth rate of 23% this year.
- Canaccord Genuity reiterated its Buy rating and kept a $65 price target ahead of the company’s upcoming fourth-quarter earnings release.
- Stifel maintained its Buy rating, pointing to notable shortfalls in traditional musculoskeletal care that Hinge Health seeks to address.
- Piper Sandler adjusted its price target down from $71 to $60 while retaining an Overweight rating; the firm cited analyses of quarterly member behavior and revised financial projections.
- Wells Fargo initiated coverage with an Overweight rating and a $68 price target, highlighting Hinge Health’s leadership within the musculoskeletal category and its competitive positioning.
Taken together, these broker notes underscore persistent institutional interest in Hinge Health’s growth trajectory and market placement within the digital MSK care industry. The sector itself has experienced consolidation activity, as evidenced by the Sword Health-Kaia Health transaction referenced by Citizens.
Investors and market observers will be watching Hinge Health’s February 10 quarterly report closely for updated operating metrics and any commentary on member behavior and forward guidance that could influence near-term analyst views.
Summary
Citizens reaffirmed a Market Outperform and $65 price target on Hinge Health following due diligence, highlighting a sizeable upside from the then-current share price. The update arrives amid consolidation in the digital MSK sector and just ahead of Hinge Health’s scheduled Q4 2025 earnings release on February 10.